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Abstract 
Objectives: Metabolic syndrome causes complications like cardiovascular disease and type 2 diabetes 
mellitus (T2DM). As metabolic syndrome develops, altered levels of cytokines and microRNAs 
(miRNA) are measurable in the circulation. We aimed to construct a panel detecting abnormal levels of 
cytokines and miRNAs in patients at risk for metabolic syndrome. Methods: Participants included 54 
patients from a Family Medicine Clinic at Marshall University School of Medicine, in groups of: Control, 
Obese, and Metabolic Syndrome (MetS). Results: Serum levels of leptin, adiponectin, leptin: 
adiponectin ratio, IL-6, six miRNAs (320a, 197-3p, 23-3p, 221-3p, 27a-3p, and 130a-3p), were measured. 
Among the three groups, leptin, and leptin: adiponectin ratio, and IL-6 levels were highest in MetS, and 
levels in Obese were greater than Control (p>0.05). Adiponectin levels were lower in Obese compared 
to Control, but lowest in MetS (p<0.05). MiRNAs levels were lowest in MetS, and levels in Obese were 
lower than Control (p>0.05). Conclusion: Our results support the clinical application of biomarkers in 
diagnosing early stage MetS, which will enable attenuation of disease progression before onset of 
irreversible complications. Since West Virginians are high-risk for developing MetS, our biomarker 
panel could reduce the disease burden on our population. 
Key words: metabolic syndrome, microRNA, serum biomarkers, West Virginia. 
Introduction 
Adults in West Virginia have the highest 
prevalence of T2DM and hypertension in the US and 
are the second most obese state in the country [1]. As 
these conditions are associated with MetS, we 
conjecture that among adults, West Virginia has a 
high prevalence of this disease. MetS manifests as an 
aggregate of disorders including hypertension, central 
obesity, hyperglycemia, dyslipidemia, and insulin 
resistance. The nature of MetS is multi-factorial; 
delineating mechanisms of the pathogenesis is a 
complex and unfinished task [2]. As a chronic 
disorder, MetS progresses discretely until potentially 
devastating complications arise [3-6]. Medical 
expenses of patients with MetS are higher than those 
without MetS with a 20% increase in cost for every 
additional component of MetS [7, 8]. Due to the 
indolent nature of MetS, the financial burden and the 
healthcare disparities, populations like those in West 
Virginia suffer a significant disease burden. Along 








disease management, prevention, and early 
intervention are vital components for combatting this 
disease [9]. Since this profoundly impacts our 
population, it is vital to determine a method that 
reduces MetS and associated complications [2].  
From a literature review, we extrapolated 
biomarkers suitable for inclusion in a panel for MetS 
detection [2]. Leptin is found at increased levels in 
patients with MetS and specifically with abdominal 
obesity, and insulin resistance [10] [11-13]. Increased 
adiponectin levels improve insulin sensitivity, 
vasodilation, and lipid oxidation, while protecting 
against atherogenesis [14-16]. Levels are low in people 
at risk for developing T2DM, hypertension, and 
obesity [17, 18]. The leptin to adiponectin (LAR) ratio 
overcomes the limit that exists in the values of 
adiponectin and leptin during the fasting versus 
postprandial state [19]. MetS induces an inflammatory 
state, increasing levels of the pro-inflammatory 
cytokines, such as IL-6. IL-6 levels correlate with 
elements of MetS, MetS alone, and the severity of 
MetS [20-22].  
MiRNAs are small single-stranded RNA 
molecules that alter gene expression by preventing 
translation; this happens after transcription coding 
messenger RNA is modified or silenced by miRNA 
[23, 24]. MiRNAs are transported into the circulation 
and function in various pathways such as metabolism 
[23, 25, 26]. A dysregulated metabolic process is 
caused by abnormally functioning miRNAs and is 
implicated in the development of CVD, MetS, and 
T2DM [23]. The use of miRNAs for clinical testing of 
disease is applicable since numerous studies conclude 
that a statistically significant variance exists between 
the control groups and people with metabolic disease. 
As reported in the literature, we selected miRNAs that 
correlated with components of MetS for the panel in 
our study. MiRNAs: 320a, 197-3p, 23-3p, 221-3p, 
27a-3p, and 130a-3p exhibit altered levels correlating 
with pathophysiological components of MetS [24, 25, 
27-32]. Levels of miR-320a, miR-27a-3p, miR-130a-3p, 
miR-23-a and miR-221 vary in the circulation of 
patients with MetS [25, 30, 33]. Studies revealed that 
levels of miR-130a-3p, miR-221, miR-197, and 
miR-23-a, corresponded to states of obesity [25, 30, 
33]. Circulating levels of miR-23-a, miR-197, 
miR-27a-3p, and miR-130a-3p vary in the circulation 
of patients with hypertension [25, 30, 33]. Previous 
studies demonstrated the existence of a relationship 
between varied blood glucose levels and miR-320a 
miR-197 [25, 30, 33]. In patients with known insulin 
resistance miR-130a-3p and miR-320a tend to exhibit 
variation in circulating levels [24, 25, 30]. MiRNAs 
appear to be useful for pre-clinical diagnosis, since 
they are more sensitive and specific for early 
diagnosis, risk assessment and monitoring disease 
progression [24]. MiRNAs exhibit remarkable stability 
under harsh conditions such as: pH, temperature, 
storage, and multiple freeze-thaw cycles [24, 31]. 
A panel of biomarkers used to diagnose MetS in 
the early stage, allows for prevention of debilitating 
conditions that accompany MetS [34]. In this study we 
measured serum biomarkers and miRNA associated 
with MetS. We studied a group of adult females in 
West Virginia with normal BMI, obesity and a 
diagnosis of MetS. Our objectives for this study 
included: detecting circulating levels of biomarkers 
associated with MetS in patients at risk for developing 
this disease and developing a biomarker panel 
providing early detection, risk assessment and 
monitoring of MetS. A biomarker panel for MetS, with 
the potential for prevention and early intervention, 
could greatly impact populations at high risk for the 
disease, such as the people of West Virginia [2].  
Material and Methods 
Patients 
A total of 54 adult females, visiting the Family 
Medicine Clinic at Marshall University School of 
Medicine, were enrolled in this study and each signed 
an informed consent. The patients were grouped into 
categories based on BMI and MetS diagnosis: 1. 
Control group with a BMI <30; 2. Obese group with a 
BMI ≥30 and no clinical diagnosis of MetS, and 3. 
MetS, patients carrying a clinical diagnosis of MetS. 
Patients with malignancy, trauma or age under 18 or 
over 45, were excluded from this study. Trained 
personnel followed a standard protocol to measure 
the height, weight, waist circumference (midway 
from the lowest rib to the iliac crest to the nearest 0.1 
cm), and blood pressure of each patient. BMI was 
calculated for the individual by dividing weight (kg) 
by the square of height (m). The Ethics Committee of 
the Cabell Huntington Hospital, West Virginia 
approved this study.  
Blood Samples  
Study patients had venous blood drawn from an 
antecubital vein in EDTA tubes after fasting for at 
least 8 hours. The blood obtained was intended to 
acquire levels of inflammatory cytokines, miRNA, 
blood glucose levels, and lipid panels. Blood samples 
were processed by spinning blood at 3000 rpm for 10 
minutes at 4ºC. Serum for cytokine and miRNA 
analysis was frozen at -80ºC prior to analysis. The 
laboratory, at Cabell-Huntington Hospital, analyzed 
blood for glucose levels and lipid panels; these values 
were obtained from the patient chart.  





Enzyme-linked immunosorbent assays (ELISA) 
were used to determine levels of leptin (EMD 
Millipore Corporation, Billerica, MA), HMW 
adiponectin (Abcam plc, Cambridge, UK), IL-6 (R&D 
Systems, Inc., Minneapolis, MN). All protocols 
provided by the manufacturer were followed for each 
ELISA kit.  
Extraction of miRNA 
We performed RNA extraction using the 
miRNeasy SerumPlasma Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s 
instructions. 1 ml of QIAzol reagent was added to 200 
ml of serum sample. The samples were vortexed in a 
tube, followed by the addition of 200 µl of chloroform. 
After mixing vigorously, the samples were then 
centrifuged at 12,000 g for 15 min at 4°C. The upper 
aqueous phase was transferred to a new collection 
tube, and 900 µl of absolute ethanol was added. The 
samples were then applied directly to columns and 
washed. Total RNA was eluted in 14 µl of 
nuclease-free H2O. The quality and quantity of RNA 
were evaluated by 260:280 ratio using NanoDrop 
analyzer (Thermo Scientific). For RT reaction, we used 
the miRCURY LNA Universal RT microRNA PCR Kit 
(Exiqon, Vedbaek, Denmark). Each RT reaction used 
50 ng of total RNA. Total RNA was combined with 4 
µl of 5x reaction buffer, 9 µl of nuclease-free water, 2 
µl of enzyme mix and 0.5 µl of synthetic spike-in to a 
final volume of 20 µl. The RT-PCR was set as follows 
incubated at 42°C for 1 h, heat-inactivated at 95°C for 
5 min and immediately cooled to 4°C. The expression 
levels of miRNA in serum samples were studied with 
a SYBR-based quantitative PCR using a miRNA 
specific primer and ExiLENT SYBR Green Master mix 
(Exiqon). To normalize the miRNA expression the 
internal control, the synthetic spike-in, was used. The 
expression levels of miRNA were then assessed by 
real-time quantitative PCR (qRT-PCR) according to 
the manufacturer’s instructions. A 4 µl aliquot of 40x 
diluted cDNA template was combined with 5 µl of 
SYBR green master mix and 1 µl of PCR primer mix to 
a final volume of 10 µl. Two technical replicates per 
sample were used for qRT-PCR amplification run on a 
7500 Fast Real-Time PCR Systems (Applied 
Biosystems). The sequence of miRNAs are listed 
below.  










Data analysis was performed using GraphPad 
Prism 4.0. Within each of the three patient categories, 
Bartlett’s test was applied for each biomarker to 
guarantee equal variance. For each biomarker, 
differences of statistical significance were identified in 
the average serum levels using ANOVA. Specification 
of the patient groups that showed statistically 
significant variances for the biomarker measured was 
achieved using the Turkey post-hoc test.  
Results 
In the clinic, 54 patients were recruited into the 
study and placed in one of three groups: individuals 
with a normal BMI and no MetS (n=24), obese 
individuals with no clinical diagnosis of MetS (n=17) 
and obese individuals with a clinical diagnosis of 
MetS (n=16). All participants were adults and female. 
There was no difference between the groups in the 
mean age ratio. Adult females with MetS showed 
significant differences in clinical markers compared to 
those without MetS. Additionally, obese adult females 
and adult females with MetS showed significant 
differences in the cytokines and miRNA associated 
with MetS compared to the Control patients. 
Clincial markers of MetS 
As shown in table 1, Systolic blood pressure was 
significantly elevated in Obese and MetS patients 
compared to Control (p<0.01). Fasting blood glucose 
and triglycerides were significantly elevated in 
patients with MetS only (p<0.01). HDL was decreased 
in the MetS group (p<0.01). These are the variables 
included in the IDF definition of MetS and are used to 
make the clinical diagnosis of MetS [5].  
 
Table 1. Patient Demographic and Clinical Profile.  
Values represent means ± SEM. *p<0.01 vs. Control, # p<0.01 vs. Obese. Body mass index (BMI), Fasting blood sugar (FBS), Systolic blood pressure (SBP), Diastolic blood 
pressure (DBP), Triglyceride (TG), High density lipoprotein (HDL) in Control, Obese and MetS patients. 
Groups Number of Patients Age (yrs.) BMI (kg/m2) FBS (mg/dL) SBP (mmHg) DBP(mmHg) TG (mg/dL) HDL (mg/dL) 
Control 24 33.29 (±1.4) 23.30 (±0.7) 88.05 (±1.5) 111.73 (±2.4) 69.86 (±2.1) 94 (±7.2) 62.84 (±2.9) 
Obese 17 38.5 (±2.3) 43.57 (±2.95) 87.83 (±2.2) 130.58 (±4.2)* 77.76 (±3.1) 81.5 (±7.2) 66.67 (±2.9) 
MetS  16 38.5 (±2.2) 48.5 (±3.73) 111.62 (±7.2)* # 136.3 (±4.9)* 85.75 (±1.5)* 141.86 (±9.4)* # 43.4 (±1.8)* # 





Serum cytokine biomarkers 
Adipokines, leptin and adiponectin, are 
bioactive substances released by adipocytes that 
control appetite, promote effective glucose use, and 
enhance insulin sensitivity. As adipocytes accumulate 
in obesity, these cytokines become dysregulated 
initiating MetS [2]. Compared to the Control group, 
leptin was significantly elevated in the Obese group 
and even more so in the MetS group (p<0.05), figure 1 
(A). Adiponectin was significantly decreased in the 
Obese group and more so in the MetS group 
compared to the Control (p<0.05) figure 1 (B). Obese 
patients showed significantly higher LAR to Control 
and LAR in the MetS group was the highest of the 
three groups (p<0.05) figure 1 (C). The dysregulated 
adipokines of MetS induce an inflammatory response 
and release of pro-inflammatory cytokines such as 
IL-6 into the circulation [2]. Our results show that IL-6 
was significantly highest in the MetS group and the 
Obese group had higher levels of IL-6 compared to 
Control (p<0.05) figure 1 (D). 
Circulating miRNA biomarkers 
Altered function and variable circulating levels 
of miRNAs, regulators of genetic expression, correlate 
with MetS and its components [25]. All six miRNAs 
analyzed in the circulation of these patients followed 
a similar statistically significant pattern. The 
following miRNAs: 320a, 197-3p, 23-3p, 221-3p, 
27a-3p, and 130a-3p exhibit dysregulated activity in 
the setting of MetS resulting in variable levels [24, 25, 
27-32]. Each miRNA studied showed greatest 
decrease in the circulation of the MetS group but was 
also decreased in the obese group compared to the 
Control (p<0.05); results depicted in figure 2 and 3 
(A-C respectively).  
Comparing clinical markers and serum 
biomarkers 
Mean clinical values, mean values of serum 
cytokine biomarkers and serum miRNAs were 
compared in table 2. Among the Obese group, mean 
values of systolic blood pressure, leptin, LAR, IL-6 
were significantly elevated compared to Control 
(p<0.01). Levels of adiponectin and miRNAs: 320a, 
197-3p, 23-3p, 27a-3p, 130a-3p, were significantly 
decreased in the Obese group when compared to 
Control (p<0.01). Among the MetS group, mean 
values of fasting blood sugar, systolic and diastolic 
blood pressure, triglycerides, leptin, LAR, IL-6 were 
significantly elevated compared to Control (p<0.01). 
Levels of HDL, adiponectin, and miRNAs: 320a, 
197-3p, 23-3p, 221-3p, 27a-3p, 130a-3p, were 
significantly decreased in the MetS group when 
compared to Control (p<0.01). Among the MetS 
group, mean values of 
fasting blood sugar, 
triglycerides, leptin, LAR, 
IL-6 were significantly 
elevated compared to 
Obese (p<0.01). Levels of 
HDL and miRNAs: 320a, 
197-3p, 23-3p, 27a-3p, 
130a-3p, were significantly 
decreased in the MetS 
group when compared to 
Obese (p<0.01). The 
correlation between the 
mean values of serum 
cytokine biomarkers and 
serum miRNA from all 
three groups were depicted 
in scatterplots in figures 
4-6. Adiponectin, leptin, 
and IL-6 values were 
compared to each miRNA 
individually in figures 4 





Figure 1. Cytokines. Assay of serum concentrations of (A) Leptin, (B) Adiponectin, (C) Leptin: Adiponectin Ratio, (D) 
IL-6 in Control (n=24), Obese (n=17), and MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. 
Control; # p<0.01 vs. Obese. 
 





Figure 2. Circulating miRNAs. Assay of serum concentrations of circulating (A) miR-320a, (B) miR-197-3p, and (C) miR-23-3p in Control (n=24), Obese (n=17), and 
MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. Control; # p<0.01 vs. Obese. 
 
Figure 3. Circulating miRNAs. Assay of serum concentrations of circulating (A) miR-221-3p, (B) miR-27a-3p, and (C) miR-130a-3p Control (n=24), Obese (n=17), 











Table 2. Comparing clincal markers and serum biomarkers and miRNAs 
 
Comparing mean clinical values associated with metabolic syndrome with mean serum biomarkers and serum miRNAs mean values from three groups: Control (n=24), 
Obese (n=17), and MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. Control, # p<0.01 vs. Obese. Body mass index (BMI), Fasting blood sugar (FBS), 
Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Triglyceride (TG), High density lipoprotein (HDL) in Control, Obese, and MetS patients.  
 
 
Figure 4. Correlation of adiponectin with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation 
to miR320 (r=0.55; p<0.05), (B) miR197 (r=0.477; p<0.05) (C) miR23a (r=0.51; p<0.05), (D) miR221 (r=0.46; p<0.05)), (E) miR2713p (r=0.54; p<0.01)), and (F) 
miR130a3p (r=0.54; p<0.01)). 





Figure 5. Correlation of leptin with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation to 
miR320 (r= -0.86; p<0.01), (B) miR197 (r= -0.79; p<0.01) (C) miR23a (r= -0.79; p<0.01), (D) miR221 (r= -0.54; p<0.01)), (E) miR2713p (r= -0.80; p<0.01)), and (F) 
miR130a3p (r= -0.79; p<0.01)).  
 
 
Figure 6. Correlation of IL-6 with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation to 
miR320 (r= -0.71; p<0.01), (B) miR197 (r= -0.61; p<0.01) (C) miR23a (r= -0.70; p<0.01), (D) miR221 (r= -0.59; p<0.01)), (E) miR2713p (r= -0.63; p<0.01)), and (F) 
miR130a3p (r= -0.60; p<0.01)). 
 
  






Figure 7. In this scheme, the progression of MetS is represented. Once the patient is at risk for MetS, pathophysiological changes alter biomarker levels. If a 
biomarker profile permits the diagnosis of MetS in the early stage, then disease progression is impeded prior to the onset of irreversible sequel. 
 
Discussion 
The results of our study indicate that a panel of 
biomarkers has a significant role in the detection of 
early stage MetS, before irreversible complications 
develop. Our results demonstrate statistically 
significant circulating levels of cytokines and miRNA 
associated with MetS displayed in a profile unique to 
each group of our population. This shows that 
pathologic changes occurring at the cellular level are 
translated through our data prior to perceptible 
clinical markers. This approach improves the 
recognition and diagnosis of MetS and is summarized 
in the schematic diagram, figure 7. Furthermore, a 
pattern of disease progression is evident in the 
biomarker profile. These trends are unique to the 
population of adult West Virginian females with 
obesity and MetS in our study. Our study indicated 
altered levels of cytokines (leptin, adiponectin and 
IL-6) and decreased levels of miRNAs (320-a, 197-3p, 
23-3p, 221-3p, 27a-3p and 130a3p) appear in the 
circulation of patients indicating early stage MetS.  
MetS is a multifactorial disease, and delineating 
pathogenic mechanisms is complex; however, insulin 
resistance and central obesity are instrumental in 
disease development. Current strategies of 
diagnosing MetS rely on lipid, insulin and glucose 
levels, blood pressure and BMI or waist 
measurements [5]. Criteria that meet diagnosis of 
MetS indicate pathologic conditions of these levels 
and measurements. Once these indicators coincide 
with the diagnosis of MetS, complications develop 
with an increased risk of permanent disability and 
mortality, emphasizing the need to diagnose MetS in 
the early stage. 
Dysregulation of leptin and adiponectin 
contribute to the progression of MetS. Deleterious 
effects of high levels of leptin, as in MetS, include: 
angiogenesis, hypertension, atherosclerosis and 
myocardial remodeling [14, 35, 36]. Leptin levels were 
highest in the MetS group and elevated in the Obese 
group compared to Control in our results. Elevated 
levels of circulating leptin indicate the metabolic 
changes are progressing to MetS. Protective 
properties of adiponectin fade at lower levels and are 
negatively correlated with glucose, insulin, and 
triglyceride levels, as well as adipose tissue 
accumulation and elevated blood pressure [12, 35, 37]. 
Consistent with previous studies, our data identified 
decreased levels of adiponectin in the MetS and Obese 
groups, indicating that disease progression of MetS 
occurs before recognition of current clinical measures.  
The inflammatory state of MetS causes the 
release of the cytokine IL-6. In obesity, reactive 




oxygen species are formed from high levels of lipid 
oxidation, which precipitates systemic stress and the 
release of inflammatory cytokines [38]. In this 
dysregulated environment, IL-6 activates receptors to 
induce insulin resistance. IL-6 damages vascular 
endothelium to initiate atherosclerotic plaque 
formation [39-41]. Circulating levels of IL-6 correlate 
with the severity of MetS [20-22]. In our data, IL-6 was 
increased in the Obese and even more so in the MetS 
group establishing congruity between elevation of 
this biomarker and formation of an early diagnosis of 
MetS. 
From the literature we chose miRNAs: 320a, 
197-3p, 23-3p, 221-3p, 27a-3p, and 130a-3p to 
investigate in our population [24, 25, 27-32]. This 
group was selected, based on previous studies, since 
they all detect MetS in the early stage. All six miRNAs 
were significantly decreased in the circulation of the 
Obese group and even more so in the MetS group. 
This pattern indicates the value of including these 
miRNAs in a biomarker panel for MetS in our 
population. 
Levels of circulating miRNA are not uniformly 
expressed between studies, which may reflect 
intergroup variance. Expression of miR-320a is 
dysregulated within insulin-resistant adipocytes [25, 
30, 33]. A study of patients with T2DM in the United 
Kingdom found levels of circulating miR-320a 
decreased in of patients with T2DM [32]. Conversely, 
a study from Singapore detected a positive correlation 
between circulating miR-320a and fasting blood 
glucose levels, up regulation of miR-320a levels in 
patients with MetS and T2DM was also observed [25]. 
In a group of Asian Indians, miR-197 negatively 
correlated with the level of glycemic impairment and 
also decreased in T2DM and among a different Asian 
population, miR-197 was down regulated in MetS [29, 
32]. However, other studies reveal that circulating 
miR-197 levels are increased in MetS, decreased in 
hypertension and positively correlated with elevated 
BMI [25, 30, 33]. MiR-23-a is associated with several 
metabolic pathways such as: glucose homeostasis, 
insulin secretion, lipid and carbohydrate metabolism 
[31]. In a study of adult Chinese females, the levels 
were distinct in patients with pre-diabetes versus 
T2DM [31]. Circulating amounts of miR-23a vary, but 
are positively correlated with BMI, increased in MetS, 
decreased in T2DM and hypertension [25]. MiR-221 
displays decreased expression in obesity [24, 33]. 
However, among a group of Chinese women, 
circulating levels of miR-221-3p were higher in 
non-obese with MetS [27]. Physical activity and 
bariatric surgery increased the expression of 
miR-221-3p; known to be down regulated in the 
circulation and adipocytes of obese individuals [30, 
42]. MiR-27a-3p is a regulator in adipogenic pathways 
and studies report that levels are increased MetS and 
in T2DM, but decreased in hypertension [25, 27, 33]. 
Circulating miR-130a-3p exhibited variability as 
decreased levels in obesity, T2DM and cardiovascular 
disease, while levels were increased in MetS, 
hypertension and insulin resistance; diets low in 
glycemic index, decreases the expression of 
circulating miR-130a-3p [24, 25, 30]. 
MiRNAs are targets for therapeutic strategies 
since they are key regulators in various pathways of 
disease. Monitoring miRNA in the circulation could 
provide: evaluation of disease progression, risk, 
susceptibility, treatment while offering a confirmation 
of a preclinical diagnosis [24]. One study examined 
intergroup differences of circulating miRNAs 
associated with T2DM. Levels of MiR-144 were 
significantly high in a Swedish population with 
T2DM but not in Iraqis; ethnic variation could explain 
this difference [28]. Levels of miRNA signal variation 
between the sexes may account for the sex differences 
found in the cardiovascular sequela of MetS [27]. 
Whether this difference results from diversity of 
genetics, environment, diet or lifestyle remains to be 
determined. The use of miRNAs in clinical testing of 
disease is applicable as numerous studies find that 
they exhibit a statistically significant variance 
between healthy and metabolic diseased individuals. 
MiRNAs appear to be a useful addition to a panel of 
biomarkers for pre-clinical diagnosis, risk assessment, 
and monitoring progression of MetS [24].  
Biomarkers, like cytokines and miRNA, allow 
clinicians to diagnose, manage and stratify a patient’s 
risk for disease states as depicted in figure 7 
(schematic). Clinical application of a panel for MetS 
could prompt early detection and intervention before 
development of systemic complications. Since 
biomarkers have roles in various pathways, a panel of 
several biomarkers increases the specificity and 
sensitivity of disease detection. The panel could 
profoundly impact populations affected by this 
disease, such as the people of West Virginia.  
Conclusion 
 MetS places a major disease burden on the 
population of West Virginia. Although further 
research is necessary to determine the predictive 
value of the considered serum biomarkers and 
miRNAs in regards to MetS, our results demonstrate 
that the biomarkers and miRNAs studied all showed 
a significant correlation to the disease states of MetS 
and obesity in a population of West Virginia females. 
Our formulated biomarker and miRNA panel has 
significant potential for detection of MetS and 
attenuation of disease progression prior to onset of 




irreversible complications. In turn, this could reduce 
the disease burden of MetS on our West Virginia 
population. 
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